ArticlePloS one2025
Uricase deficiency in rats results in a variety of metabolic disorders, addition to gouty nephropathy.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical evidence suggests that hyperuricemia is frequently associated with hyperglycemia (diabetes), hyperlipidemia, and hypertension. However, this relationship has not been fully verified in experimental animals. The present study used uricase-deficient rats (KDY rats, n = 125) with spontaneously elevated levels of serum uric acid (SUA) as the model animals and investigated their metabolic conditions throughout their lifespan (626 days of age). The serum, urine and feces of the rats were collected, histological examination was performed using hematoxylin-eosin or Masson's staining, and gene expression was determined using transcriptome high-throughput sequencing. Compared with wild type (WT) rats of the same age, the SUA levels in KDY rats were continuously high (approximately 70 μg/mL), and the body weight gain slowed after 45 days of age, followed by increased urine output, diabetes mellitus (hyperglycemia), high low-density lipoprotein, and hypercholesterolemia. Histological examination showed that gouty nephropathy appeared after approximately 45 days of age, before the rats developed medullary injury, medullary interstitial fibrosis, cortical glomerulus injury, and glomerular fibrosis. KDY rats also showed signs of atherosclerosis and hypertension in the late stage of their lifespan. The lifespan of KDY rats was significantly shorter than that of WT rats (more than 626 days). The expected lifespan of KDY rats is approximately 450 days, and the direct cause of the shortened lifespan is renal failure caused by gout nephropathy. The direct mechanisms of the lesions in KDY are related to the upregulation of various of inflammatory (immune) pathways. In conclusion, it demonstrated that hyperuricemia in KDY rats leads to type 2 diabetes mellitus (hyperglycemia), hyperlipidemia, atherosclerosis, and hypertension, in addition to gouty nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.